More HIV Research Highlights From CROI 2018
March 7, 2018
Our coverage from the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston continued yesterday with three interviews with federal HIV leaders who shared perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.
NIH's Dr. Carl Dieffenbach Discussed Interim Results on a Study of a Vaginal Ring for HIV Prevention and Studies About Heart Disease Among PLWH
Turning to another topic under discussion at CROI this week, Dr. Dieffenbach noted researcher interest in heart disease. It is a leading non-infectious comorbidity of HIV and was the topic of several presentations. He reminded us that people living with HIV are as much as twice as likely to develop cardiovascular disease (CVD) than people who do not have HIV. He urged viewers living with HIV who are over 45 years of age to talk to their healthcare provider about getting a CVD workup. He also shared that NIAID is running the REPRIEVE trial, which is testing whether a daily dose of a statin reduces the risk of heart disease among people living with HIV who are at low to moderate CVD risk and are on antiretroviral therapy. The trial is still enrolling participants. Visit the REPRIEVE trial website for more information. (See our February Heart Health Month blog post for more information.)
HRSA's Dr. Laura Cheever Reflects on Moving Research Into Clinical Practice and More
We also had the opportunity to visit with Dr. Laura Cheever who leads the Ryan White HIV/AIDS Program as HRSA's Associate Administrator for the HIV/AIDS Bureau. She reflected on how conferences like CROI historically have helped disseminate new HIV research, how the Ryan White Program has and continues to train clinicians on implementing those advances in our understanding of the care and treatment of HIV, and what she saw as some promising innovations presented at this year's conference. She also discussed a symposium held the previous day at CROI about improving the HIV care cascade in the United States, observing that this is something that the Ryan White Programs works hard to address. In fact, the most recent data show that the viral suppression among clients has increased from 69% in 2010 to 85% today. We can't be sure, but Dr. Cheever may also have been taking some notes at CROI to inform the 2018 National Ryan White Conference on HIV Care and Treatment that will take place December 11-14, 2018.
CDC's Dr. Dawn Smith Discussed First-Ever PrEP Data by Race and Ethnicity
In another Facebook Live interview, we learned about a new CDC analysis presented at CROI that found that only a small percentage of Americans who could benefit from pre-exposure prophylaxis (PrEP), a daily pill for HIV prevention, have been prescribed it. CDC's Dr. Dawn Smith, Biomedical Interventions Lead for the Division of HIV/AIDS Prevention, discussed this first detailed analysis by race and by risk group. CDC researchers found, she explained, that while two-thirds of people who could potentially benefit from PrEP are African-American or Latino, they account for the smallest percentage of prescriptions to date. She also highlighted some of the barriers to access to PrEP experienced by some people, and steps CDC is taking to support both healthcare providers and patients with information and tools to expand the awareness of and use of PrEP. Learn more about this study: view our interview above with Dr. Smith, view her CROI presentation, and read CDC's news release about the study.
[Note from TheBodyPRO: This article was originally published by HIV.gov on March 7, 2018. We have cross-posted it with their permission.]
This article was provided by HIV.gov. It is a part of the publication The 25th Conference on Retroviruses and Opportunistic Infections.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.